Lyles A. 2002. Direct marketing of pharmaceuticals to consumers. Annu Rev Public Health 23:73-91.

MHRA. 2006. Black Triangle Scheme. [Online]. Available: http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON024119 [accessed July 13, 2006].

Mintzes B, Barer ML, Kravitz RL, Bassett K, Lexchin J, Kazanjian A, Evans RG, Pan R, Marion SA. 2003. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Can Med Assoc J 169(5):405-412.

Nickas J. 2006 (January 19). A Biotechnology Industry Perspective. PowerPoint presentation to the Institute of Medicine Committee on the Assessment of the US Drug Safety System, Meeting Four. Washington, DC: IOM.

Ostrove NM. 2000 (August 8-9). FDA’s Research About Consumer-Directed Prescription Drug Promotion. PowerPoint presentation at Pharmaceutical Pricing Practices, Utilization and Costs.

Palumbo FB, Mullins CD. 2002. The development of direct-to-consumer prescription drug advertising regulation. Food Drug Law J 57(3):423-443.

Pines WL. 1999. A history and perspective on direct-to-consumer promotion. Food Drug Law J 54(4):489-518.

Ray WA, Stein CM. 2006. Reform of drug regulation—beyond an independent drug-safety board. N Engl J Med 354(2):194-201.

Ritter J. 2006. Acne Drug Registry Irritates Patients: Rules for Avoiding Pregnancy. [Online]. Available: http://www.findarticles.com/p/articles/mi_qn4155/is_20060821/ai_n16674372 [accessed August 21, 2006].

Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. 2002. Promotion of prescription drugs to consumers. N Engl J Med 346(7):498-505.

Spence M, Cheetham C, Millares M, Teleki S, Schweitzer S. 2005 (November 1-2). Direct-to-Consumer Advertising of Cox-2 Inhibitors: Effect on Appropriateness of Treatment. Presented at the FDA Public Hearing on Comsumer-Directed Promotion of Medical Products. Washington, DC: FDA.

Steenburg C. 2006. The Food and Drug Administration’s use of postmarketing (phase IV) study requirements: exception to the rule? Food Drug Law J 61(2):1-91.

Thaul S. 2005. Drug Safety and Effectiveness: Issues and Action Options After FDA Approval. [Online]. Available: http://www.law.umaryland.edu/marshall/crsreports/crsdocuments/RL3279703082005.pdf [accessed June 27, 2005].

van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH. 2003. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 163(15):1801-1807.

Washington Legal Foundation. 2005. WLF Launches “FDA/DDMAC Watch”. [Online]. Available: http://www.wlf.org/upload/062105RS.pdf [accessed October 10, 2005].

Weissman JS, Blumenthal D, Silk AJ, Newman M, Zapert K, Leitman R, Feibelmann S. 2004. Physicians report on patient encounters involving direct-to-consumer advertising. Health Aff Web Exclusive:W4-W219.

Wilkes MS, Bell RA, Kravitz RL. 2000. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Aff (Millwood) 19(2):110-128.

Winter G. 2005. Inside DDMAC: A Conversation with Thomas Abrams. [Online]. Available: http://www.pharmexec.com/pharmexec/content/printContentPopup.jsp?id=256550 [accessed December 1, 2005].

Woodcock J, DHHS, FDA. 2003. Statement by Janet Woodcock, MD Director, Center for Drug Evaluation and Research US Drug Administration, Department of Health and Human Services, July 22, 2003, before the Senate Special Committee on Aging.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement